Teva shares approach 20-year low amid Moody’s warning and other woes

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 16, 2019 at 12:02 AM.

  1. #1 cafead, Aug 16, 2019 at 12:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Debt-rating firm Moody's revised its Teva outlook from "stable" to "negative" as the company deals with challenges ranging from opioid lawsuits to a congressional price-fixing probe to declining sales of its MS drug Copaxone. Investors were none too happy.

    article source
     
    Quote

Reply to Thread